{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AIN457&page=2", "query": { "intervention": "AIN457", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AIN457&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-16T16:22:11.956Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01892436", "title": "Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Secukinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 460, "start_date": "2013-09-30", "completion_date": "2018-01-11", "has_results": true, "last_update_posted_date": "2019-06-12", "last_synced_at": "2026-09-16T16:22:11.956Z", "location_count": 22, "location_summary": "Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 18 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Upland", "state": "California" }, { "city": "Tamarac", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01892436" }, { "nct_id": "NCT04209205", "title": "Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "AIN457 6 mg/kg i.v.", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "AIN457 3 mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 381, "start_date": "2020-01-29", "completion_date": "2022-05-17", "has_results": true, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-09-16T16:22:11.956Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Fountain Valley, California • Fullerton, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04209205" }, { "nct_id": "NCT01989468", "title": "24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Secukinumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 414, "start_date": "2014-04-10", "completion_date": "2018-03-28", "has_results": true, "last_update_posted_date": "2019-04-16", "last_synced_at": "2026-09-16T16:22:11.956Z", "location_count": 12, "location_summary": "Aventura, Florida • Palm Harbor, Florida • Sarasota, Florida + 9 more", "locations": [ { "city": "Aventura", "state": "Florida" }, { "city": "Palm Harbor", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Bowling Green", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01989468" }, { "nct_id": "NCT01806597", "title": "Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Palmoplantar Psoriasis" ], "interventions": [ { "name": "secukinumab 150 mg", "type": "BIOLOGICAL" }, { "name": "secukinumab 300 mg", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 205, "start_date": "2013-06-19", "completion_date": "2016-11-02", "has_results": true, "last_update_posted_date": "2018-02-22", "last_synced_at": "2026-09-16T16:22:11.956Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Indianapolis, Indiana + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01806597" }, { "nct_id": "NCT01640951", "title": "4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Chronic Plaque-Type Psoriasis" ], "interventions": [ { "name": "AIN457 150 mg", "type": "DRUG" }, { "name": "AIN457 300 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 675, "start_date": "2012-09-16", "completion_date": "2017-05-04", "has_results": true, "last_update_posted_date": "2018-05-25", "last_synced_at": "2026-09-16T16:22:11.956Z", "location_count": 28, "location_summary": "Fresno, California • Pasadena, California • San Francisco, California + 24 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01640951" }, { "nct_id": "NCT00809159", "title": "Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ankylosing Spondylitis" ], "interventions": [ { "name": "AIN457", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2009-03", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2015-12-09", "last_synced_at": "2026-09-16T16:22:11.956Z", "location_count": 10, "location_summary": "Paradise Valley, Arizona • Springfield, Illinois • Oklahoma City, Oklahoma + 6 more", "locations": [ { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Springfield", "state": "Illinois" }, { "city": "Springfield", "state": "Illinois" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Duncansville", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00809159" }, { "nct_id": "NCT01377012", "title": "Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Secukinumab (AIN457)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 637, "start_date": "2011-08-30", "completion_date": "2015-09-09", "has_results": true, "last_update_posted_date": "2017-03-29", "last_synced_at": "2026-09-16T16:22:11.956Z", "location_count": 39, "location_summary": "Mesa, Arizona • Paradise Valley, Arizona • Peoria, Arizona + 34 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01377012" }, { "nct_id": "NCT01109940", "title": "Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ankylosing Spondylitis" ], "interventions": [ { "name": "AIN457A", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 39, "start_date": "2010-04", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2021-06-24", "last_synced_at": "2026-09-16T16:22:11.956Z", "location_count": 9, "location_summary": "Paradise Valley, Arizona • Springfield, Illinois • Oklahoma City, Oklahoma + 5 more", "locations": [ { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Springfield", "state": "Illinois" }, { "city": "Springfield", "state": "Illinois" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Duncansville", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01109940" }, { "nct_id": "NCT03350815", "title": "Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Ankylosing Spondylitis" ], "interventions": [ { "name": "150 mg open-label secukinumab", "type": "DRUG" }, { "name": "150 mg double-blinded secukinumab", "type": "DRUG" }, { "name": "300 mg double-blinded secukinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 322, "start_date": "2018-03-13", "completion_date": "2021-05-29", "has_results": true, "last_update_posted_date": "2022-04-29", "last_synced_at": "2026-09-16T16:22:11.956Z", "location_count": 65, "location_summary": "Jonesboro, Arkansas • Fullerton, California • Loma Linda, California + 60 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Palm Desert", "state": "California" }, { "city": "Tustin", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03350815" }, { "nct_id": "NCT01132612", "title": "AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plaque-type Psoriasis" ], "interventions": [ { "name": "AIN457", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2010-05-11", "completion_date": "2016-10-18", "has_results": true, "last_update_posted_date": "2018-01-04", "last_synced_at": "2026-09-16T16:22:11.956Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Pasadena, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Pasadena", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01132612" } ] }